Nissay Asset Management Corp Neurocrine Biosciences Inc Transaction History

Nissay Asset Management Corp

$16.7 Billion
Q2 2025

A detailed history of Nissay Asset Management Corp transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Nissay Asset Management Corp holds 12,250 shares of NBIX stock, worth $1.75 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

12,250

Previous 12,293 0.35%

Holding current value

$1.75 Million

Previous $1.36 Million 13.25%

% of portfolio

0.01%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$87.54 - $128.18 $3,764 - $5,511	-43 Reduced 0.35%	12,250 $1.54 Million
Q1 2025 May 15, 2025	BUY	$107.22 - $153.29 $11,472 - $16,402	107 Added 0.88%	12,293 $1.36 Million
Q4 2024 Feb 14, 2025	BUY	$111.62 - $139.44 $16,296 - $20,358	146 Added 1.21%	12,186 $1.66 Million
Q3 2024 Nov 14, 2024	BUY	$114.58 - $153.15 $53,394 - $71,367	466 Added 4.03%	12,040 $1.39 Million
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $52,474 - $57,419	401 Added 3.59%	11,574 $1.59 Million
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $30,383 - $33,491	233 Added 2.13%	11,173 $1.54 Million
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $37,548 - $46,997	354 Added 3.34%	10,940 $1.44 Million
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $33,283 - $41,453	354 Added 3.46%	10,586 $1.19 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $17,100 - $20,030	-191 Reduced 1.83%	10,232 $964,000
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $37,832 - $49,454	-402 Reduced 3.71%	10,423 $1.06 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $25,292 - $30,113	-237 Reduced 2.14%	10,825 $1.29 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $39,664 - $46,466	431 Added 4.05%	11,062 $1.18 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $9,852 - $13,009	-130 Reduced 1.21%	10,631 $1.04 Million
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $19,199 - $25,124	265 Added 2.52%	10,761 $1.01 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $33,373 - $44,506	419 Added 4.16%	10,496 $894,000
Q3 2021 Nov 10, 2021	BUY	$86.18 - $99.03 $35,247 - $40,503	409 Added 4.23%	10,077 $966,000
Q2 2021 Aug 13, 2021	BUY	$89.43 - $102.27 $39,349 - $44,998	440 Added 4.77%	9,668 $941,000
Q1 2021 May 11, 2021	SELL	$87.57 - $119.4 $19,440 - $26,506	-222 Reduced 2.35%	9,228 $897,000
Q4 2020 Feb 08, 2021	BUY	$86.91 - $108.33 $31,113 - $38,782	358 Added 3.94%	9,450 $906,000
Q3 2020 Oct 20, 2020	BUY	$96.16 - $135.15 $22,789 - $32,030	237 Added 2.68%	9,092 $874,000
Q2 2020 Jul 27, 2020	BUY	$85.09 - $130.36 $98,619 - $151,087	1,159 Added 15.06%	8,855 $1.08 Million
Q1 2020 May 05, 2020	BUY	$75.11 - $113.76 $23,884 - $36,175	318 Added 4.31%	7,696 $666,000
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $640,410 - $874,809	7,378 New	7,378 $793,000

Others Institutions Holding NBIX

# of Institutions

683

Shares Held

102M

Call Options Held

290K

Put Options Held

214K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.7B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nissay Asset Management Corp , based on Form 13F filings with the SEC.

News

Stay updated on Nissay Asset Management Corp with notifications on news.

Account

Nissay Asset Management Corp Neurocrine Biosciences Inc Transaction History